BTIG Reiterates Buy on Bright Minds Biosciences, Maintains $147 Price Target
BTIG analyst Thomas Shrader reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $147 price target.
Read original at benzingaStocks · News reference
HC Wainwright & Co. Reiterates Buy on Bright Minds Biosciences, Maintains $145 Price Target
HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Bright Minds Biosciences (NASDAQ:DRUG) with a Buy and maintains $145 price target.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 19, 2026, 3:12 PM
- Checked
- Aug 19, 2026, 3:12 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading